126 related articles for article (PubMed ID: 24629929)
21. Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling.
Baliram R; Sun L; Cao J; Li J; Latif R; Huber AK; Yuen T; Blair HC; Zaidi M; Davies TF
J Clin Invest; 2012 Oct; 122(10):3737-41. PubMed ID: 22996689
[TBL] [Abstract][Full Text] [Related]
22. [Effect of the bone resorption supernatant from RAW264.7 osteoclast on the osteogenic activity of mouse MC3T3-E1 cell].
Chen LL; Wang K; Zhang J; Wu YM
Zhonghua Kou Qiang Yi Xue Za Zhi; 2012 Jan; 47(1):32-7. PubMed ID: 22490219
[TBL] [Abstract][Full Text] [Related]
23. Genetic confirmation for a central role for TNFα in the direct action of thyroid stimulating hormone on the skeleton.
Sun L; Zhu LL; Lu P; Yuen T; Li J; Ma R; Baliram R; Moonga SS; Liu P; Zallone A; New MI; Davies TF; Zaidi M
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9891-6. PubMed ID: 23716650
[TBL] [Abstract][Full Text] [Related]
24. Autophagy-linked FYVE containing protein WDFY3 interacts with TRAF6 and modulates RANKL-induced osteoclastogenesis.
Wu DJ; Gu R; Sarin R; Zavodovskaya R; Chen CP; Christiansen BA; Zarbalis KS; Adamopoulos IE
J Autoimmun; 2016 Sep; 73():73-84. PubMed ID: 27330028
[TBL] [Abstract][Full Text] [Related]
25. IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.
Kitami S; Tanaka H; Kawato T; Tanabe N; Katono-Tani T; Zhang F; Suzuki N; Yonehara Y; Maeno M
Biochimie; 2010 Apr; 92(4):398-404. PubMed ID: 20045440
[TBL] [Abstract][Full Text] [Related]
26. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice.
Marians RC; Ng L; Blair HC; Unger P; Graves PN; Davies TF
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15776-81. PubMed ID: 12432094
[TBL] [Abstract][Full Text] [Related]
27. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
28. Low‑molecular weight fucoidan inhibits the differentiation of osteoclasts and reduces osteoporosis in ovariectomized rats.
Jin X; Zhu L; Li X; Jia J; Zhang Y; Sun X; Ma J; Liu Z; Ma X
Mol Med Rep; 2017 Feb; 15(2):890-898. PubMed ID: 28000877
[TBL] [Abstract][Full Text] [Related]
29. Effect of CD44 deficiency on in vitro and in vivo osteoclast formation.
de Vries TJ; Schoenmaker T; Beertsen W; van der Neut R; Everts V
J Cell Biochem; 2005 Apr; 94(5):954-66. PubMed ID: 15578568
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts.
Zhang F; Tanaka H; Kawato T; Kitami S; Nakai K; Motohashi M; Suzuki N; Wang CL; Ochiai K; Isokawa K; Maeno M
Biochimie; 2011 Feb; 93(2):296-305. PubMed ID: 20937352
[TBL] [Abstract][Full Text] [Related]
31. Novel bioactivity of phosvitin in connective tissue and bone organogenesis revealed by live calvarial bone organ culture models.
Liu J; Czernick D; Lin SC; Alasmari A; Serge D; Salih E
Dev Biol; 2013 Sep; 381(1):256-75. PubMed ID: 23791550
[TBL] [Abstract][Full Text] [Related]
32. Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair.
Georgy SR; Pagel CN; Ghasem-Zadeh A; Zebaze RM; Pike RN; Sims NA; Mackie EJ
Bone; 2012 Mar; 50(3):704-12. PubMed ID: 22173052
[TBL] [Abstract][Full Text] [Related]
33. High bone mass in mice lacking Cx37 because of defective osteoclast differentiation.
Pacheco-Costa R; Hassan I; Reginato RD; Davis HM; Bruzzaniti A; Allen MR; Plotkin LI
J Biol Chem; 2014 Mar; 289(12):8508-20. PubMed ID: 24509854
[TBL] [Abstract][Full Text] [Related]
34. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function.
Furlan F; Galbiati C; Jorgensen NR; Jensen JE; Mrak E; Rubinacci A; Talotta F; Verde P; Blasi F
J Bone Miner Res; 2007 Sep; 22(9):1387-96. PubMed ID: 17539736
[TBL] [Abstract][Full Text] [Related]
35. Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone.
Johnson RW; McGregor NE; Brennan HJ; Crimeen-Irwin B; Poulton IJ; Martin TJ; Sims NA
Bone; 2015 Dec; 81():343-351. PubMed ID: 26255596
[TBL] [Abstract][Full Text] [Related]
36. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
[TBL] [Abstract][Full Text] [Related]
38. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
39. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
40. The cellular actions of interleukin-11 on bone resorption in vitro.
Hill PA; Tumber A; Papaioannou S; Meikle MC
Endocrinology; 1998 Apr; 139(4):1564-72. PubMed ID: 9528935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
